| Literature DB >> 27682873 |
Suraj Peri1, Elena Caretti2, Rossella Tricarico2, Karthik Devarajan1, Mitchell Cheung3, Eleonora Sementino3, Craig W Menges3, Emmanuelle Nicolas3, Lisa A Vanderveer4, Sharon Howard5, Peggy Conrad6, James A Crowell7, Kerry S Campbell5, Eric A Ross1, Andrew K Godwin8, Anthony T Yeung4, Margie L Clapper4, Robert G Uzzo3,9, Elizabeth P Henske10, Christopher J Ricketts11, Cathy D Vocke11, W Marston Linehan11, Joseph R Testa3,9, Alfonso Bellacosa2, Levy Kopelovich12, Alfred G Knudson3.
Abstract
Tumor suppressor genes and their effector pathways have been identified for many dominantly heritable cancers, enabling efforts to intervene early in the course of disease. Our approach on the subject of early intervention was to investigate gene expression patterns of morphologically normal "one-hit" cells before they become hemizygous or homozygous for the inherited mutant gene which is usually required for tumor formation. Here, we studied histologically non-transformed renal epithelial cells from patients with inherited disorders that predispose to renal tumors, including von Hippel-Lindau (VHL) disease and Tuberous Sclerosis (TSC). As controls, we studied histologically normal cells from non-cancerous renal epithelium of patients with sporadic clear cell renal cell carcinoma (ccRCC). Gene expression analyses of VHLmut/wt or TSC1/2mut/wt versus wild-type (WT) cells revealed transcriptomic alterations previously implicated in the transition to precancerous renal lesions. For example, the gene expression changes in VHLmut/wt cells were consistent with activation of the hypoxia response, associated, in part, with the "Warburg effect". Knockdown of any remaining VHL mRNA using shRNA induced secondary expression changes, such as activation of NFκB and interferon pathways, that are fundamentally important in the development of RCC. We posit that this is a general pattern of hereditary cancer predisposition, wherein haploinsufficiency for VHL or TSC1/2, or potentially other tumor susceptibility genes, is sufficient to promote development of early lesions, while cancer results from inactivation of the remaining normal allele. The gene expression changes identified here are related to the metabolic basis of renal cancer and may constitute suitable targets for early intervention.Entities:
Keywords: TSC1; TSC2; VHL; primary kidney epithelial cells; transcriptomics
Mesh:
Substances:
Year: 2017 PMID: 27682873 PMCID: PMC5392274 DOI: 10.18632/oncotarget.12192
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Gene expression patterns, as heatmap, between VHLmut/wt and wild-type (WT) renal epithelial cells (A), and between TSC1/2mut/wt and WT renal epithelial cells (B) U, up-regulated; D, down-regulated.
Gene Ontology (GO) categories (biological processes) enriched for both up and down-regulated genes in one-hit VHL cells
| GOBPID | Term | Genes |
|---|---|---|
| GO:0043981 | histone acetylation | MEAF6,PHF17,PHF16 |
| GO:0007093 | mitotic cell cycle checkpoint | ZWINT,RPS27L,CCNA2,CCNB1,BUB3 |
| GO:0034101 | erythrocyte homeostasis | FOXO3,ARNT,LYN,PRDX1,ACVR1B,SFXN1 |
| GO:0030099 | myeloid cell differentiation | FOXO3,ARNT,LYN,PSEN1,TGFBR2,CASP8,SCIN,ACVR1B,SFXN1,CDC42 |
| GO:0043161 | proteasomal ubiquitin-dependent protein catabolic process | ERLIN2,HSPA5,HSP90AB1,PSMA6,PSMA7,PSMD5,RAD23B,DERL1,CCNB1,BUB3 |
| GO:0009060 | aerobic respiration | IDH1,SDHB,UQCRH,CAT,SUCLG1 |
| GO:0045454 | cell redox homeostasis | PDIA6,DNAJC16,PDIA3,GSR,PRDX1,TXNDC12,SELT,PDIA4 |
| GO:0042542 | response to hydrogen peroxide | TXNIP,PRDX1,APTX,SLC8A1,CASP6,CAT |
| GO:0006979 | response to oxidative stress | TXNIP,IDH1,ARNT,PRDX1,APTX,PSEN1,SLC8A1,TPM4,CASP6,ATRN,CAT |
| GO:0006511 | ubiquitin-dependent protein catabolic process | UBE4B,ERLIN2,FBXO21,RNF144B,HSPA5,HSP90AB1,PSMA6,PSMA7,PSMD5,RAD23B,UBE2G1,DERL1,CCNB1,BUB3 |
| GO:0055114 | oxidation reduction | SLC25A13,KDM5B,HIBADH,EGLN3,COX15,CYP51A1,ALDH9A1,KDM1A,GLUD1,GSR,HADHA,HCCS,HGD,IDH1,MAOA,ALDH6A1,P4HA1,PRDX1,TXNDC12,RDH11,PCYOX1,KDM3B,OGFOD1,PECR,SDHB,SQLE,UQCRH,CYB5B,CAT |
| Downregulated Biological Processes | ||
| GO:0070584 | mitochondrion morphogenesis | DNM1L,COL4A3BP,OPA1 |
| GO:0000045 | autophagic vacuole assembly | ATG4B,C12orf44,ATG9A |
| GO:0008629 | induction of apoptosis by intracellular signals | CDKN1A,C16orf5,PML,UACA,AEN,CUL4A |
| GO:0046626 | regulation of insulin receptor signaling pathway | GRB14,PTPRF,RELA,TSC2 |
| GO:0032570 | response to progesterone stimulus | RELA,TGFB1,THBS1,FOSL1 |
| GO:0008286 | insulin receptor signaling pathway | AKT2,GRB14,PHIP,PTPRF,RELA,TSC2 |
| GO:0043536 | positive regulation of blood vessel endothelial cell migration | PDGFB,TGFB1,THBS1 |
| GO:0007179 | transforming growth factor beta receptor signaling pathway | LTBP2,MEN1,PDGFB,PML,TGFB1,TGFB1I1,THBS1,USP9Y,LTBP4 |
| GO:0001952 | regulation of cell-matrix adhesion | CDK6,RASA1,THBS1,TSC2 |
| GO:0007162 | negative regulation of cell adhesion | COL1A1,ARHGDIA,RASA1,TGFB1,THBS1 |
| GO:0010810 | regulation of cell-substrate adhesion | CDK6,COL1A1,RASA1,THBS1,TSC2 |
| GO:0009411 | response to UV | CDKN1A,MEN1,PML,ATR,TMEM161A,UACA,RELA |
| GO:0042770 | DNA damage response, signal transduction | CDKN1A,C16orf5,PML,ATR,UACA,AEN,FBXO31,CEP63 |
| GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | CDKN1A,C16orf5,PML,ATR,AEN |
| GO:0007050 | cell cycle arrest | CDKN1A,GAS2L1,MEN1,PML,MAPK12,TGFB1,THBS1,SESN2,CUL4A |
| GO:0031571 | G1/S DNA damage checkpoint | CDKN1A,PML,FBXO31 |
| GO:0031575 | G1/S transition checkpoint | CDKN1A,PML,TGFB1,FBXO31 |
| GO:0007064 | mitotic sister chromatid cohesion | PDS5B,NIPBL |
| GO:0030036 | actin cytoskeleton organization | SORBS3,FMNL2,DAAM1,FLNA,RND3,RHOG,PDGFB,CCDC88A,RAC2,RASA1,ROCK1,TSC2,CALD1,DIAPH3,PDLIM7,CYTH2,ARHGEF17 |
The enrichment analysis was done using GO-Stats package (Bioconductor). Categories were selected based on p-value cutoff < 0.01.
Figure 2Pathways showing involvement of TCA cycle, Warburg effect, AKT-mTOR (yellow, gray and green background, respectively), and HIF in
-single hit cells. Genes depicted in green indicate down-regulation, and red indicate up-regulation in VHL-single hit cells vs. WT cells. Genes not colored and shown in gray color are not differentially expressed. VHL-single hit cells show partial activation of Warburg effect, whereby entry of pyruvate into TCA cycle is restricted due to activation of PDK, whereas other arm of the Warburg effect through HIF activation of glucose transporter and glycolysis is not active. mTOR-mediated transcriptional activation of HIF is active. *, genes experimentally validated.
Figure 3A. Summary of averaged 2-NBDG fluorescence, indicating glucose uptake for 5 WT and 5 VHL-single hit cultures. B. Summary of averaged lactate concentration for 5 WT and 5 VHL-single hit cultures. C. Box plots of differential GLUT1 expression between VHLmut/wt vs. WT cells, as determined with indicated Affymetrix probes.
Figure 4Heatmap of glycolysis, TCA cycle, HIF and AKT pathway genes depicting fold-changes in
-single hit cells and different kidney malignancies compared to their respective normal kidney epithelium (from studies in Supplemental Table 1). ccRCC, clear cell RCC; pRCC, papillary RCC; trans-cRCC, transitional cell RCC. Datasets normalized using RMA and LIMMA were used to calculate fold -changes (no p-value cutoff was enforced). Green and red color in heatmap indicates down- and up-regulation in RCC or VHLmut/wt cells, whereas gray indicates no fold change. Brown indicates VHL-single hit cells; cyan indicates studies of ccRCC, including comparisons based on VHL mutation status, a) among sporadic tumors with loss of two copies vs. one copy of VHL loss; b) VHL two-hit sporadic tumor vs. familial VHL loss cases; purple indicates chromophobe; magenta indicates oncocytoma; blue indicates papillary; and beige indicates transitional-cell RCC. Genes in matrix were hierarchically clustered (average linkage with uncentered Pearson correlation).
Figure 5Enrichment analysis of the transcriptomic profile of
-null cells, i.e., comparison of VHL-single hitVHL knockdown vs. VHL-single hitpLKOcontrol. A. Enrichment plot for IFNB and TLR pathways. B. Pathways enriched for down-regulated genes (mitosis and DNA replication pathways in Reactome database). C. Leading edge analysis of up-regulated genes contributing to enrichment of pathway sets curated for interferon and anti-viral signaling pathways, depicted as heatmap (red and blue color indicate over- and underexpression of genes in VHL-single hitVHL knockdown cells).
Gene Ontology (GO) categories (biological processes) enriched for both up and down-regulated genes in one-hit TSC1/2 cells
| GOBPID | Term | a3 |
|---|---|---|
| GO:0010986 | positive regulation of lipoprotein particle clearance | LIPG |
| GO:0060074 | synapse maturation | ERBB4 |
| GO:0051301 | cell division | CAT,CCNA2,CCNG2,CDK1 |
| GO:0007095 | mitotic cell cycle G2/M transition DNA damage checkpoint | CCNA2 |
| GO:0043551 | regulation of phosphoinositide 3-kinase activity | VAV3 |
| GO:0050847 | progesterone receptor signaling pathway | UBR5 |
| GO:0030518 | steroid hormone receptor signaling pathway | UBR5,MED14 |
| GO:0051973 | positive regulation of telomerase activity | PARM1 |
| GO:0042542 | response to hydrogen peroxide | ERBB4,CAT |
| GO:0009101 | glycoprotein biosynthetic process | MGAT4A,ST8SIA4,CHST9 |
| Downregulated biological processes | ||
| GO:0007568 | aging | CDKN2A,CRYAB,SERPINE1 |
| GO:0001300 | chronological cell aging | SERPINE1 |
| GO:0002691 | regulation of cellular extravasation | ICAM1 |
| GO:0022614 | membrane to membrane docking | ICAM1,VCAM1 |
| GO:0042110 | T cell activation | CDKN2A,ICAM1,VCAM1 |
| GO:0033079 | immature T cell proliferation | CDKN2A |
| GO:0032836 | glomerular basement membrane development | WT1 |
| GO:0010389 | regulation of G2/M transition of mitotic cell cycle | CDKN2A |
| GO:0031641 | regulation of myelination | CDH2 |
| GO:0000302 | response to reactive oxygen species | CRYAB,SERPINE1 |
The enrichment analysis was done using GO-Stats package (Bioconductor). Categories were selected based on p-value cutoff < 0.01.